Finance

Lists
TRLV:NYSE
Trulieve Cannabis Corp
$11.31
-0.09%
(-0.0100) 1D
$11.18
-1.13% (-0.13)
After hours
Closed: Sep 11, 4:00:04 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TRLV...
Open
$11.52
High
$11.75
Low
$11.15
Mkt. cap
2.18B
Avg. vol.
1.27M
Volume
1.51M
52-wk high
$12.76
52-wk low
$7.82
EPS
-$2.46
Beta
1.75
Shares outstanding
170.16M
No. of employees
5K
Open
$11.52
High
$11.75
Low
$11.15
Mkt. cap
2.18B
Avg. vol.
1.27M
Volume
1.51M
52-wk high
$12.76
52-wk low
$7.82
EPS
-$2.46
Beta
1.75
Shares outstanding
170.16M
No. of employees
5K
News stories
From web sources and news partners
About Trulieve Cannabis Corp
CEO-
Employees5K
FoundedSep 14, 1940
Headquarters-
SectorPharmaceutical industry
Websitetrulieve.com
Analyst ratings
Based on 3 analysts giving stock ratings to TRLV in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for TRLV in the last 3 months.
Highest
Current $11.31
$20.00 (+76.83%)
Average
$17.42 (+54.02%)
Lowest
$15.00 (+32.63%)
Analyst
Recommendation
Action
Price target
Projected
Date
Neal Gilmer
Haywood
Buy
Reiterated
$17.25
+52.5%
08/07/2026
Aaron Grey
Alliance Global Partners
Buy
Maintained
$20.00
+76.8%
08/07/2026
Unknown Analyst
Cantor Fitzgerald
Buy
Initiated
$15.00
+32.6%
07/20/2026
Gabrielle Ingoglia
Cantor Fitzgerald
Buy
Initiated
$15.00
+32.6%
07/20/2026
Bill Kirk
Roth MKM
Buy
Reiterated
$19.00
+68%
06/05/2026
Luke Hannan
Canaccord Genuity
Buy
Reiterated
CA$28.00
+147.6%
05/08/2026
Last report
Aug 7, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.11 / $0.03
+266.67%beat
Revenue / Est. (USD)
270.95M / 268.26M
+1.00%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
288.19M
293.10M
286.75M
270.95M
Cost of goods sold
118.33M
118.00M
116.67M
108.66M
Cost of revenue
118.33M
118.00M
116.67M
108.66M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
99.02M
126.30M
104.90M
101.77M
Operating expense
128.48M
155.70M
134.64M
127.49M
Total operating expenses
246.80M
273.70M
251.31M
236.15M
Operating income
41.38M
19.40M
35.44M
34.80M
Other non operating income
-1.24M
600.00K
132.00K
-403.22M
EBT including unusual items
29.30M
2.90M
25.22M
-383.40M
EBT excluding unusual items
28.44M
8.70M
24.94M
-381.41M
Income tax expense
53.04M
47.90M
21.86M
21.97M
Effective tax rate
181.00%
1,651.72%
86.67%
-5.73%
Other operating expenses
-
-
-
-
Net income
-26.84M
-42.90M
2.41M
-405.98M
Net profit margin
-9.31%
-14.64%
0.84%
-149.83%
Earnings per share
-0.07
-0.02
0.10
0.11
Interest and investment income
4.39M
3.40M
2.68M
3.06M
Interest expense
-16.09M
-14.70M
-13.32M
-12.76M
Net interest expenses
-11.69M
-11.30M
-10.64M
-9.70M
Depreciation and amortization charges
29.46M
29.40M
29.74M
25.72M
EBITDA
84.79M
63.00M
79.18M
73.95M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps